Press release

GamaMabs Pharma, a biotechnology company developing optimized therapeutic antibodies targeting the Anti-Müllerian Hormone Receptor II (AMHRII) for the treatment of cancer, today announces the upcoming presentation of clinical data from the First-In-Human C101 phase Ia/Ib study of its GM102 antibody during the American Society of Clinical Oncology (ASCO) Annual Meeting, on June 4 in Chicago, USA.

To read the full statement of GamaMabs Pharma, click here.

Contact us

I am a business person
I am an investor
Please contact communication@anderapartners.com for further information
Please contact investors@anderapartners.com for further information
Please send us your application to rh@anderapartners.com